Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TFPI


Brief Information

Name:Tissue factor pathway inhibitor
Target Synonym:TFPI,Tissue Factor Pathway Inhibitor,Extrinsic Pathway Inhibitor,TFPI1,LACI,EPI,Anti-Convertin,TFI,Lipoprotein-associated coagulation inhibitor,Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
Cat. No. Species Product Description Structure Purity Feature
TFI-H8226 Human Biotinylated Human TFPI Protein, His Tag, ultra sensitivity (primary amine labeling)
TFI-H5226 Human Human TFPI Protein, His Tag (active enzyme)
ACRO Quality

Synonym Name



Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a N­terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C­terminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The C­terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Concizumab NNC-0172-2021; NNC-172-2021; mAbTFPI2021; NN-7415; NNC-0172-0000-2021; Anti-TFPI; mAb-2021 Approved Novo Nordisk A/S Alhemo Japan Hemophilia A; Hemophilia B Novo Nordisk Pharma Ltd 2023-09-25 Hemophilia A; Hemophilia B; Hemorrhage Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
MG-1113 MG-1113 Phase 1 Clinical GC Biopharma Corp Hemophilia A Details
KN-057 KN-057 Phase 3 Clinical Suzhou Alphamab Co Ltd Hemophilia A; Hemophilia B Details
Befovacimab BAY-109; BAY-1093884 Phase 1 Clinical Morphosys Ag, Bayer AG Hemophilia A; Hemophilia B Details
AP-017 AP017; AP-017 Phase 1 Clinical Anyuan Pharmaceutical Technology (Shanghai) Co Ltd Hemophilia A; Hemophilia B Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message